SCHEMBL30891768

SCHEMBL30891768

COc1cc2ncnc(-c3ccc(NC(=O)Cc4ccc(C(F)(F)F)cc4)cc3)c2cc1OCCCN1CC2(CCOCC2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.51
KDR P35968 8/20 0.48
EGFR P00533 6/20 0.48
BRAF P15056 2/20 0.48
FLT1 P17948 2/20 0.47
FLT4 P35916 2/20 0.47
AURKA O14965 5/20 0.47
MET P08581 4/20 0.47
AURKB Q96GD4 2/20 0.47
ROCK2 O75116 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
RET P07949 1/20 0.47
MAPT P10636 1/20 0.47
SRC P12931 1/20 0.47
PDGFRA P16234 1/20 0.47
LTK P29376 1/20 0.47
TTK P33981 1/20 0.47
MAP2K2 P36507 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30394060 0.93 EGFR (0.52) EPHX2KDREGFRBRAFFLT1
SCHEMBL30394605 0.91 KDR (0.51) EPHX2KDREGFRBRAFFLT1
SCHEMBL26099881 0.91 KDR (0.51) EPHX2KDREGFRBRAFFLT1
SCHEMBL30393137 0.91 EPHX2 (0.61) EPHX2KDREGFRBRAFFLT1
SCHEMBL26535728 0.91 EPHX2 (0.61) EPHX2KDREGFRBRAFFLT1
SCHEMBL30393178 0.91 KDR (0.48) EPHX2KDREGFRBRAFFLT1
SCHEMBL26101851 0.91 KDR (0.48) EPHX2KDREGFRBRAFFLT1
SCHEMBL30394201 0.89 KDR (0.49) EPHX2KDREGFRBRAFFLT1
SCHEMBL26136652 0.88 KDR (0.60) EPHX2KDRFLT1FLT4AURKA
SCHEMBL31137798 0.87 AURKA (0.57) EPHX2KDREGFRFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 CN claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB EPHX2 1313/4885KDR 5/4885EGFR 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.